8-K: Glucotrack Secures $3M in Zero-Interest Convertible Note

Glucotrack, Inc. has issued a $3.6 million principal convertible promissory note for $3 million cash, bearing zero interest and convertible upon a qualified financing.

Summary

• Issued a Convertible Promissory Note with a principal amount of $3,600,000.
• Received a cash purchase price of $3,000,000, resulting in an original issue discount of $600,000.
• The Note bears zero percent (0%) interest per annum.
• Maturity date is the earlier of the twelve-month anniversary of the issue date (September 12, 2026) or the closing of a Qualified Financing.
• A Qualified Financing is defined as an issuance and sale of capital stock generating at least $5,000,000 in gross proceeds to the Company.
• The Note is convertible into equity securities at the Qualified Financing price, with a floor price of $4.871 per share for Common Stock.
• The Company must use 100% of net proceeds from its existing $20.0 million Equity Line of Credit (ELOC) with Sixth Borough Capital Fund, LP to repay the Note until stockholder approval is obtained for ELOC share issuance beyond the Exchange Cap.
• After stockholder approval, 50% of net ELOC proceeds will be used for Note repayment.
• The Note was issued in a private placement to an accredited investor under Section 4(a)(2) and Rule 506(b) of the Securities Act.

Sentiment

Score: 6

Explanation: The Company secured $3 million in non-dilutive cash upfront with zero interest, which is positive for immediate liquidity. However, the $600,000 original issue discount and the mandatory repayment from ELOC proceeds, potentially limiting other uses of ELOC funds, introduce some negative aspects. The conversion terms also carry potential for future dilution.

Positives

• Secured $3,000,000 in immediate cash funding.
• The convertible note bears zero interest, reducing immediate debt servicing costs.
• The Company retains flexibility with the option to prepay the note at any time without investor consent.
• The ELOC repayment mechanism provides a structured path for debt reduction, leveraging future equity sales.

Negatives

• The note has an original issue discount of $600,000, meaning the Company received less cash than the principal amount it is obligated to repay or convert.
• The requirement to use 100% (and later 50%) of ELOC proceeds for note repayment could limit the Company's immediate access to capital from the ELOC for other operational needs.
• Conversion at a Qualified Financing price, with a floor, could lead to significant dilution for existing shareholders if the Qualified Financing occurs at a low valuation.

Risks

• Failure to secure a Qualified Financing or generate sufficient ELOC proceeds could lead to the Note becoming due in cash on the maturity date, potentially straining liquidity.
• The conversion price floor of $4.871 per share could result in substantial dilution if future equity is issued at or near this price.
• The Company's ability to obtain stockholder approval for ELOC share issuance beyond the Exchange Cap is a condition for reducing the ELOC repayment percentage to 50%.
• Events of default, including bankruptcy or failure to perform covenants, could trigger immediate repayment of the entire Note Balance.
• The Note and any securities issued upon conversion are unregistered and subject to transfer restrictions, limiting liquidity for the investor.

Future Outlook

The Company anticipates potentially raising at least $5,000,000 in a future Qualified Financing, which would trigger the conversion of the note. It also plans to utilize its existing Equity Line of Credit to generate proceeds, a portion of which will be used to repay the note, subject to obtaining stockholder approval for larger share issuances.

Management Comments

• Paul Goode, PhD, Chief Executive Officer, signed the Note and the 8-K filing.

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential for future dilution if the convertible note is converted at the floor price or a low Qualified Financing price. The mandatory use of ELOC proceeds for note repayment could affect the pace of ELOC utilization for other corporate purposes.
• Creditors: The note is an unsecured obligation and ranks equally with existing and future unsecured indebtedness.

Next Steps

• Obtain stockholder approval to issue Purchase Shares under the ELOC in excess of the Exchange Cap.
• Potentially conduct a "Qualified Financing" to raise at least $5,000,000, which would trigger the conversion of the note.
• Utilize the Equity Line of Credit to sell shares and generate proceeds for note repayment.

Key Dates

Recommendation

The financing provides immediate capital with zero interest, which is a positive for liquidity. However, the original issue discount and the mandatory use of ELOC proceeds for repayment, coupled with potential future dilution from conversion, present a mixed picture. The company is actively managing its capital structure, but the long-term impact depends on the terms of future financings and operational performance. Investors should hold and monitor the execution of the ELOC and any Qualified Financing.

Keywords

Glucotrack, Convertible Note, Promissory Note, Private Placement, Equity Line of Credit, ELOC, Capital Raise, Debt Financing, GCTK, Accredited Investor, Zero Interest